ablynx nv (ABLX:Euronext Brussels)
Edwin Moses Ph.D.
Chief Executive Officer, Director and Member of Research & Development Committee, Ablynx NV
|Age||Total Calculated Compensation||This person is connected to 37 board members in 6 different organizations across 9 different industries.|
See Board Relationships
Dr. Edwin Moses, Ph.D. serves as the Chief Executive Officer of Ablynx NV and served as its Chief Executive Officer since June 6, 2006. Dr. Moses served as a Consultant of Evotec AG (formerly Evotec Oai AG) since June 7, 2005. Dr. Moses has over twenty-five years experience in the life sciences and biotechnology sectors. He has worked for many leading companies in a senior capacity including Amersham International, Oxford Asymmetry International plc and Evotec OAI. Dr. ...
Technologiepark 21Phone: 32 9 262 00 00
Ghent, East Flanders 9052
Fax: 32 9 262 00 01
Board Members Memberships*
Non-Executive Chairman, Chairman of Audit Committee, Chairman of Nominations Committee and Member of Remuneration Committee
Former Executive Chairman
Former Non-Executive Director
Non-Executive Chairman, Chairman of Nomination Committee, Chairman of Remuneration Committee and Member of Audit Committee
Former Non-Executive Director, Member of Audit Committee and Member of Remuneration Committee
Chief Executive Officer, Director and Member of Research & Development Committee
The University of Sheffield
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Daniel M. Junius||Chief Executive Officer, President and Director|
|Simon E. Moroney Ph.D.||Chairman of Management Board and Chief Executive Officer|
|Michael S. O. Oredsson B.Int’l Bus Admin (Lund)||Chief Executive Officer and President|
BioInvent International AB
|John Dawson||Chief Executive Officer and Executive Director|
Oxford BioMedica PLC
|William J. Polvino M.D.||Chief Executive Officer and President|
Veloxis Pharmaceuticals A/S
|--||Compensation as of Fiscal Year 2014.|